Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.49 |
| ▸ | ATR | Q13535 | 2/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13423695 | 1.00 | PDK2 (0.53) | PDK2HRH3KDM1AJAK2JAK1 | |
| SCHEMBL774880 | 0.83 | KDM1A (0.57) | KDM1A | |
| SCHEMBL10293555 | 0.78 | L3MBTL3 (0.69) | PDK2HRH3KDM1AL3MBTL3ATR | |
| SCHEMBL10293598 | 0.78 | L3MBTL3 (0.69) | PDK2HRH3KDM1AL3MBTL3ATR | |
| SCHEMBL3217208 | 0.78 | NAMPT (0.55) | L3MBTL3L3MBTL1 | |
| SCHEMBL3218307 | 0.78 | SMN1; SMN2 (0.51) | L3MBTL3MGLLL3MBTL1 | |
| SCHEMBL2889406 | 0.77 | MCHR1 (0.73) | HRH3L3MBTL3ATRMCHR1HDAC1 | |
| SCHEMBL3220345 | 0.76 | ACLY (0.50) | KDM1AUSP30HDAC1 | |
| SCHEMBL3216306 | 0.76 | TSHR (0.71) | MGLL | |
| SCHEMBL3218211 | 0.76 | SIGMAR1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | PDK2 1177/4885HRH3 4743/4885KDM1A 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.